Renal	B-DS
Angiomyolipoma	I-DS
:	O
The	O
Good	O
,	O
the	O
Bad	O
,	O
and	O
the	O
Ugly	O

Angiomyolipomas	B-DS
(	O
AMLs	B-DS
)	O
are	O
the	O
most	O
common	O
benign	B-DS
renal	I-DS
tumours	I-DS
.	O

Most	O
of	O
these	O
neoplasms	B-DS
are	O
found	O
incidentally	O
on	O
imaging	O
.	O

However	O
,	O
symptomatic	O
presentation	O
does	O
exist	O
.	O

Renal	B-DS
AMLs	I-DS
are	O
typically	O
composed	O
of	O
smooth	O
muscle	O
,	O
blood	O
vessels	O
,	O
and	O
adipose	O
tissue	O
.	O

Because	O
of	O
the	O
abundant	O
fat	O
tissue	O
,	O
they	O
give	O
a	O
characteristic	O
appearance	O
on	O
imaging	O
and	O
are	O
therefore	O
easily	O
diagnosed	O
.	O

However	O
,	O
sometimes	O
they	O
contain	O
too	O
little	O
fat	O
to	O
be	O
detected	O
.	O

This	O
increases	O
the	O
difficulty	O
in	O
differentiating	O
them	O
from	O
renal	B-DS
cell	I-DS
carcinoma	I-DS
(	O
RCC	B-DS
).	O

Management	O
of	O
AML	B-DS
is	O
based	O
on	O
clinical	O
presentation	O
and	O
should	O
be	O
individualized	O
for	O
every	O
patient	O
.	O

Treatment	O
modalities	O
range	O
from	O
active	O
surveillance	O
to	O
more	O
invasive	O
approaches	O
.	O

Introduction	O

Angiomyolipomas	B-DS
(	O
AMLs	B-DS
)	O
are	O
the	O
most	O
frequent	O
benign	B-DS
renal	I-DS
tumour	I-DS
,	O
with	O
a	O
prevalence	O
varying	O
between	O
0	O
.	O
2	O
%	O
and	O
0	O
.	O
6	O
%	O
and	O
a	O
strong	O
female	O
predilection	O
.	O

They	O
occur	O
as	O
sporadic	O
,	O
isolated	O
entities	O
in	O
80	O
%	O
of	O
cases	O
.	O

The	O
remaining	O
20	O
%	O
of	O
AMLs	B-DS
develop	O
in	O
association	O
with	O
tuberosclerosis	B-DS
complex	I-DS
(	O
TSC	B-DS
)	O
or	O
pulmonary	B-DS
lymphangioleiomyomatosis	I-DS
(	O
LAM	B-DS
)	O
[	O
12	O
].	O

AMLs	B-DS
are	O
considered	O
as	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	B-DS
.	O

Many	O
types	O
display	O
different	O
pathology	O
,	O
radiological	O
features	O
,	O
and	O
clinical	O
behaviour	O
,	O
although	O
they	O
all	O
consist	O
of	O
variable	O
proportions	O
of	O
the	O
same	O
three	O
elements	O
:	O
smooth	O
muscle	O
,	O
blood	O
vessels	O
,	O
and	O
adipose	O
tissue	O
[	O
23	O
].	O

Imaging	O
plays	O
a	O
central	O
role	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
renal	B-DS
AMLs	I-DS
.	O

The	O
detection	O
of	O
adipose	O
tissue	O
is	O
the	O
fundamental	O
diagnostic	O
criterion	O
of	O
a	O
classic	O
AML	B-DS
[	O
2	O
].	O

However	O
,	O
a	O
minority	O
of	O
AMLs	B-DS
lack	O
visually	O
detectable	O
fat	O
on	O
imaging	O
,	O
making	O
it	O
harder	O
to	O
distinguish	O
from	O
renal	B-DS
cell	I-DS
carcinoma	I-DS
(	O
RCC	B-DS
).	O

Therefore	O
,	O
accurate	O
preoperative	O
diagnosis	O
of	O
renal	B-DS
AMLs	I-DS
is	O
critical	O
to	O
prevent	O
unnecessary	O
nephrectomies	O
and	O
preserve	O
renal	O
functions	O
[	O
4	O
].	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
provide	O
a	O
radiological	O
classification	O
of	O
renal	B-DS
AML	I-DS
that	O
contributes	O
to	O
the	O
understanding	O
and	O
diagnosis	O
of	O
the	O
different	O
types	O
and	O
the	O
appropriate	O
therapeutic	O
management	O
and	O
follow	O
-	O
up	O
.	O

Classifications	O

Clinical	O
Classification	O

About	O
80	O
%	O
of	O
AMLs	B-DS
present	O
as	O
isolated	O
entities	O
,	O
most	O
commonly	O
manifesting	O
in	O
middle	O
-	O
aged	O
women	O
.	O

They	O
tend	O
to	O
be	O
single	O
and	O
small	O
and	O
rarely	O
progress	O
to	O
cause	O
significant	O
morbidity	O
[	O
35	O
].	O

In	O
the	O
remainder	O
20	O
%	O
of	O
cases	O
,	O
AMLs	B-DS
occur	O
in	O
association	O
with	O
TSC	B-DS
or	O
,	O
less	O
commonly	O
,	O
as	O
part	O
of	O
LAM	B-DS
.	O

Relative	O
to	O
the	O
sporadic	O
form	O
of	O
AML	B-DS
,	O
these	O
hereditary	O
lesions	O
affect	O
both	O
genders	O
equally	O
and	O
manifest	O
at	O
a	O
younger	O
age	O
.	O

They	O
are	O
likely	O
to	O
be	O
multiple	O
,	O
large	O
,	O
and	O
bilateral	O
,	O
and	O
are	O
prone	O
to	O
grow	O
and	O
be	O
more	O
aggressive	O
[	O
357	O
].	O

AMLs	B-DS
are	O
observed	O
in	O
approximately	O
75	O
%	O
of	O
patients	O
with	O
TSC	B-DS
.	O

TSC	B-DS
is	O
an	O
autosomal	B-DS
dominant	I-DS
multisystem	I-DS
disorder	I-DS
characterized	O
by	O
the	O
development	O
of	O
benign	B-DS
tumours	I-DS
(	O
hamartomas	B-DS
)	O
in	O
multiple	O
organs	O
throughout	O
the	O
body	O
.	O

The	O
main	O
organs	O
involved	O
are	O
the	O
brain	O
,	O
skin	O
,	O
lung	O
,	O
and	O
kidney	O
[	O
8	O
].	O

TSC	B-DS
is	O
caused	O
by	O
mutations	O
in	O
one	O
of	O
two	O
genes	O
,	O
TSC1	B-GP
and	O
TSC2	B-GP
,	O
which	O
encode	O
the	O
proteins	O
hamartin	B-GP
and	O
tuberin	B-GP
,	O
respectively	O
.	O

These	O
proteins	O
interact	O
with	O
each	O
other	O
to	O
form	O
a	O
tumour	B-GP
suppressor	I-GP
complex	I-GP
,	O
which	O
inhibits	O
the	O
mammalian	B-GP
target	I-GP
of	I-GP
rapamycin	I-GP
(	O
mTOR	B-GP
)	O
pathway	O
.	O

This	O
pathway	O
is	O
important	O
for	O
angiogenesis	O
,	O
protein	O
synthesis	O
,	O
and	O
cell	O
growth	O
.	O

Defective	O
or	O
deficient	O
TSC1	B-GP
or	O
TSC2	B-GP
activity	O
leads	O
to	O
unchecked	O
activation	O
of	O
mTOR	B-GP
and	O
formation	O
of	O
characteristic	O
hamartomas	B-DS
[	O
267	O
].	O

AMLs	B-DS
may	O
also	O
develop	O
in	O
patients	O
with	O
LAM	B-DS
.	O

This	O
rare	O
disorder	O
may	O
occur	O
sporadically	O
,	O
in	O
the	O
absence	O
of	O
other	O
diseases	O
,	O
but	O
is	O
common	O
in	O
patients	O
with	O
TSC	B-DS
.	O

It	O
is	O
characterized	O
by	O
diffuse	O
interstitial	O
proliferation	O
of	O
smooth	O
muscle	O
cells	O
(	O
LAM	B-DS
cells	O
)	O
and	O
the	O
presence	O
of	O
thin	O
-	O
walled	O
cysts	O
distributed	O
throughout	O
the	O
lungs	O
.	O

These	O
LAM	B-DS
cells	O
have	O
mutations	O
in	O
the	O
same	O
TSC1	B-GP
and	O
TSC2	B-GP
genes	O
[	O
67	O
].	O

Histological	O
Classification	O

Renal	B-DS
AML	I-DS
can	O
be	O
classified	O
histologically	O
as	O
typical	O
(	O
triphasic	O
)	O
or	O
atypical	O
(	O
monophasic	O
or	O
epithelioid	O
)	O
[	O
5	O
].	O

Most	O
AMLs	B-DS
contain	O
all	O
three	O
components	O
,	O
namely	O
dilated	O
blood	O
vessels	O
(	O
angio	O
),	O
smooth	O
muscle	O
cells	O
(	O
myo	O
),	O
and	O
mature	O
adipocytes	O
(	O
lipo	O
),	O
in	O
various	O
proportions	O
.	O

They	O
are	O
classified	O
as	O
triphasic	O
tumours	B-DS
.	O

However	O
,	O
some	O
tumours	B-DS
consist	O
almost	O
exclusively	O
of	O
one	O
component	O
,	O
while	O
other	O
elements	O
are	O
present	O
in	O
very	O
small	O
amounts	O
.	O

They	O
are	O
called	O
monophasic	O
.	O

At	O
last	O
,	O
the	O
epithelioid	O
variant	O
of	O
AML	B-DS
contains	O
numerous	O
epithelioid	O
muscle	O
cells	O
with	O
abundant	O
eosinophilic	O
and	O
granular	O
cytoplasm	O
and	O
few	O
or	O
no	O
fat	O
cells	O
.	O

These	O
tumours	B-DS
have	O
a	O
tendency	O
toward	O
malignant	O
transformation	O
and	O
can	O
be	O
locally	O
aggressive	O
.	O

Histologically	O
,	O
they	O
can	O
resemble	O
and	O
be	O
misdiagnosed	O
as	O
RCC	B-DS
.	O

However	O
,	O
distinction	O
of	O
epithelioid	O
AMLs	B-DS
from	O
RCC	B-DS
is	O
possible	O
by	O
the	O
presence	O
of	O
immunohistochemistry	O
markers	O
,	O
such	O
as	O
smooth	O
muscle	O
markers	O
(	O
caldesmon	B-GP
and	O
smooth	B-GP
muscle	I-GP
actin	I-GP
)	O
and	O
melanocytic	O
markers	O
(	O
HMB	O
-	O
45	O
antigen	O
and	O
melan	B-GP
-	I-GP
A	I-GP
)	O
[	O
2345	O
].	O

Radiological	O
Classification	O

There	O
is	O
a	O
growing	O
body	O
of	O
literature	O
describing	O
findings	O
and	O
techniques	O
that	O
may	O
be	O
used	O
to	O
distinguish	O
renal	B-DS
AMLs	I-DS
.	O

A	O
lack	O
of	O
a	O
generally	O
accepted	O
and	O
standardized	O
terminology	O
or	O
classification	O
of	O
AML	B-DS
fuels	O
the	O
persisting	O
confusion	O
.	O

In	O
this	O
review	O
,	O
a	O
radiological	O
classification	O
reported	O
by	O
two	O
groups	O
of	O
authors	O
will	O
be	O
discussed	O
.	O

A	O
recent	O
article	O
hypothesized	O
that	O
renal	B-DS
AMLs	I-DS
can	O
be	O
classified	O
according	O
to	O
CT	O
and	O
MRI	O
findings	O
using	O
quantitative	O
values	O
.	O

They	O
classified	O
these	O
tumours	B-DS
as	O
fat	O
-	O
rich	O
,	O
fat	O
-	O
poor	O
,	O
or	O
fat	O
-	O
invisible	O
,	O
based	O
on	O
the	O
amount	O
of	O
fat	O
detected	O
on	O
imaging	O
studies	O
.	O

To	O
distinguish	O
these	O
different	O
types	O
,	O
a	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
was	O
placed	O
in	O
the	O
most	O
hypodense	O
area	O
of	O
the	O
lesion	O
to	O
measure	O
the	O
attenuation	O
value	O
.	O

A	O
lesion	O
was	O
defined	O
as	O
fat	O
-	O
rich	O
when	O
the	O
ROI	O
measured	O
≤	O
–	O
10	O
Hounsfield	O
units	O
(	O
HU	O
)	O
on	O
unenhanced	O
CT	O
(	O
UECT	O
).	O

However	O
,	O
UECT	O
could	O
not	O
differentiate	O
fat	O
-	O
poor	O
from	O
fat	O
-	O
invisible	O
AML	B-DS
.	O

Therefore	O
chemical	O
shift	O
imaging	O
(	O
CSI	O
)	O
MRI	O
was	O
introduced	O
.	O

This	O
modality	O
provides	O
a	O
higher	O
sensitivity	O
for	O
fat	O
detection	O
than	O
UECT	O
.	O

As	O
in	O
UECT	O
,	O
the	O
most	O
signal	O
-	O
dropped	O
area	O
was	O
detected	O
and	O
a	O
ROI	O
was	O
placed	O
within	O
.	O

On	O
CSI	O
-	O
MRI	O
,	O
fat	O
-	O
poor	O
AML	B-DS
was	O
characterized	O
when	O
the	O
tumour	O
-	O
to	O
-	O
spleen	O
ratio	O
(	O
TSR	O
)	O
was	O
<	O
0	O
.	O
71	O
or	O
the	O
signal	O
intensity	O
index	O
(	O
SII	O
)	O
was	O
>	O
16	O
.	O
5	O
%.	O

Because	O
of	O
too	O
little	O
fat	O
,	O
fat	O
-	O
invisible	O
AML	B-DS
was	O
defined	O
having	O
a	O
TSR	O
≥	O
0	O
.	O
71	O
and	O
a	O
SII	O
≤	O
16	O
.	O
5	O
%	O
[	O
910	O
].	O

This	O
classification	O
showed	O
an	O
almost	O
perfect	O
inter	O
-	O
reader	O
agreement	O
,	O
which	O
means	O
it	O
is	O
feasible	O
for	O
radiologists	O
to	O
apply	O
in	O
practice	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
understand	O
that	O
detection	O
of	O
the	O
most	O
hypodense	O
area	O
on	O
CT	O
or	O
most	O
signal	O
-	O
dropped	O
area	O
on	O
MRI	O
and	O
placement	O
of	O
the	O
ROI	O
within	O
is	O
crucial	O
.	O

A	O
mislocation	O
or	O
inappropriate	O
size	O
of	O
the	O
ROI	O
may	O
change	O
the	O
type	O
of	O
AML	B-DS
,	O
with	O
misclassification	O
and	O
unwanted	O
procedures	O
as	O
a	O
result	O
.	O

Another	O
disadvantage	O
is	O
the	O
fact	O
that	O
different	O
CT	O
and	O
MR	O
scanners	O
may	O
produce	O
different	O
attenuation	O
numbers	O
and	O
signal	O
intensities	O
,	O
leading	O
to	O
a	O
wrong	O
classification	O
.	O

For	O
example	O
,	O
if	O
an	O
AML	B-DS
is	O
measured	O
–	O
9	O
HU	O
at	O
one	O
CT	O
scanner	O
,	O
it	O
will	O
be	O
classified	O
as	O
fat	O
-	O
poor	O
.	O

However	O
,	O
if	O
another	O
scanner	O
describes	O
the	O
lesion	O
as	O
–	O
11	O
HU	O
,	O
it	O
will	O
be	O
classified	O
as	O
fat	O
-	O
rich	O
.	O

Although	O
the	O
difference	O
of	O
2	O
HU	O
is	O
very	O
minimal	O
and	O
probably	O
insignificant	O
,	O
the	O
management	O
is	O
completely	O
different	O
[	O
910	O
].	O

Another	O
review	O
article	O
proposed	O
a	O
classification	O
based	O
on	O
clinical	O
,	O
histologic	O
,	O
and	O
imaging	O
features	O
.	O

First	O
,	O
the	O
authors	O
divided	O
renal	B-DS
AMLs	I-DS
into	O
sporadic	O
and	O
hereditary	O
.	O

Histologically	O
,	O
they	O
classified	O
sporadic	O
AMLs	B-DS
into	O
benign	O
triphasic	O
type	O
and	O
potentially	O
malignant	O
epithelioid	O
type	O
[	O
34	O
].	O

Benign	O
triphasic	O
type	O
was	O
further	O
divided	O
into	O
fat	O
-	O
rich	O
and	O
fat	O
-	O
poor	O
AML	B-DS
using	O
imaging	O
modalities	O
.	O

While	O
fat	O
-	O
rich	O
AML	B-DS
contained	O
enough	O
fat	O
to	O
be	O
detected	O
on	O
UECT	O
(	O
ROI	O
≤	O
–	O
10	O
HU	O
),	O
fat	O
-	O
poor	O
AML	B-DS
did	O
not	O
.	O

Fat	O
-	O
poor	O
AML	B-DS
was	O
further	O
classified	O
into	O
three	O
subtypes	O
,	O
based	O
on	O
the	O
amount	O
and	O
distribution	O
of	O
adipocytes	O
within	O
the	O
lesion	O
and	O
other	O
imaging	O
features	O
:	O
hyperattenuating	O
AML	B-DS
,	O
isoattenuating	O
AML	B-DS
,	O
and	O
AML	B-DS
with	O
epithelial	O
cysts	O
.	O

Hyperattenuating	O
AML	B-DS
was	O
hyperattenuating	O
compared	O
to	O
renal	O
parenchyma	O
on	O
UECT	O
(>	O
45	O
HU	O
),	O
homogeneously	O
enhancing	O
on	O
contrast	O
enhanced	O
CT	O
,	O
and	O
T2	O
-	O
hypointense	O
on	O
MRI	O
.	O

On	O
the	O
contrary	O
,	O
isoattenuating	O
AML	B-DS
was	O
characterized	O
by	O
attenuation	O
numbers	O
close	O
to	O
renal	O
parenchyma	O
on	O
UECT	O
(	O
between	O
–	O
10	O
and	O
45	O
HU	O
).	O

These	O
lower	O
attenuation	O
levels	O
were	O
caused	O
by	O
the	O
presence	O
of	O
fat	O
cells	O
,	O
sufficient	O
in	O
quantity	O
to	O
lower	O
the	O
overall	O
attenuation	O
relative	O
to	O
hyperattenuating	O
AMLs	B-DS
,	O
but	O
too	O
few	O
in	O
one	O
area	O
to	O
be	O
detected	O
on	O
regular	O
imaging	O
.	O

Finally	O
,	O
AMLs	B-DS
with	O
epithelial	O
cysts	O
could	O
be	O
distinguished	O
by	O
the	O
presence	O
of	O
epithelial	O
cysts	O
,	O
with	O
the	O
non	O
-	O
cystic	O
parts	O
appearing	O
similar	O
to	O
hyperattenuating	O
AML	B-DS
.	O

Radiological	O
features	O
of	O
this	O
rare	O
subtype	O
could	O
not	O
be	O
fully	O
described	O
,	O
due	O
to	O
the	O
lack	O
of	O
data	O
[	O
34	O
].	O

Epithelioid	O
AMLs	B-DS
,	O
that	O
can	O
be	O
potentially	O
malignant	O
and	O
metastasize	O
,	O
showed	O
hyperattenuation	O
on	O
UECT	O
,	O
heterogeneously	O
enhancement	O
on	O
contrast	O
enhanced	O
CT	O
,	O
and	O
T2	O
-	O
hypointensity	O
on	O
MRI	O
.	O

These	O
findings	O
were	O
caused	O
by	O
the	O
epithelioid	O
muscle	O
component	O
and	O
the	O
intratumoral	O
haemorrhage	O
and	O
necrosis	O
[	O
3410	O
].	O

There	O
are	O
limitations	O
associated	O
with	O
the	O
classification	O
described	O
above	O
.	O

First	O
,	O
the	O
requirement	O
of	O
clinical	O
and	O
pathological	O
information	O
makes	O
it	O
difficult	O
for	O
radiologists	O
to	O
use	O
in	O
daily	O
practice	O
.	O

Second	O
,	O
there	O
are	O
problems	O
in	O
applying	O
the	O
imaging	O
criteria	O
for	O
classifying	O
isoattenuating	O
AML	B-DS
.	O

The	O
authors	O
reported	O
isoattenuating	O
AML	B-DS
being	O
an	O
AML	B-DS
with	O
attenuation	O
values	O
between	O
–	O
10	O
and	O
45	O
HU	O
on	O
UECT	O
.	O

However	O
,	O
simple	O
renal	O
cysts	O
have	O
attenuation	O
numbers	O
ranging	O
between	O
–	O
10	O
and	O
10	O
and	O
appear	O
definitely	O
hypoattenuating	O
,	O
while	O
renal	O
masses	O
measuring	O
>	O
40	O
HU	O
frequently	O
appear	O
hyperattenuating	O
.	O

So	O
,	O
because	O
of	O
the	O
wide	O
range	O
of	O
AML	B-DS
attenuation	O
values	O
,	O
“	O
isoattenuating	O
AML	B-DS
”	O
does	O
not	O
seem	O
to	O
be	O
an	O
appropriate	O
term	O
.	O

Furthermore	O
,	O
the	O
authors	O
did	O
not	O
suggest	O
a	O
quantitative	O
threshold	O
for	O
CSI	O
-	O
MRI	O
,	O
which	O
means	O
that	O
radiologists	O
cannot	O
classify	O
AML	B-DS
using	O
TSR	O
or	O
SII	O
[	O
9	O
].	O

In	O
conclusion	O
,	O
the	O
classification	O
first	O
described	O
is	O
the	O
most	O
easily	O
applicable	O
in	O
practice	O
.	O

Radiologists	O
can	O
categorize	O
renal	B-DS
AMLs	I-DS
as	O
fat	O
-	O
rich	O
,	O
fat	O
-	O
poor	O
,	O
and	O
fat	O
-	O
invisible	O
,	O
according	O
to	O
the	O
amount	O
of	O
fat	O
detected	O
on	O
UECT	O
or	O
CSI	O
-	O
MRI	O
.	O

However	O
,	O
attention	O
should	O
be	O
paid	O
to	O
fit	O
the	O
ROI	O
within	O
the	O
right	O
area	O
of	O
the	O
fat	O
tissue	O
,	O
otherwise	O
many	O
fat	O
-	O
rich	O
or	O
fat	O
-	O
poor	O
AMLs	B-DS
may	O
be	O
misclassified	O
as	O
fat	O
-	O
poor	O
or	O
fat	O
-	O
invisible	O
.	O

Table	O
1	O
summarizes	O
the	O
features	O
of	O
this	O
classification	O
.	O

Radiological	O
classification	O
of	O
renal	B-DS
AML	I-DS
[	O
9	O
].	O

UECT	O
Region	O
of	O
interest	O
(	O
ROI	O
)	O

MRI	O
-	O
CSI	O
Tumour	O
-	O
to	O
-	O
spleen	O
ratio	O
(	O
TSR	O
)	O

MRI	O
-	O
CSI	O
Signal	O
intensity	O
index	O
(	O
SII	O
)	O


Fat	O
-	O
rich	O
AML	B-DS

≤	O
–	O
10	O
HU	O

<	O
0	O
.	O
71	O

>	O
16	O
.	O
5	O
%	O

Fat	O
-	O
poor	O
AML	B-DS

>	O
–	O
10	O
HU	O

<	O
0	O
.	O
71	O

>	O
16	O
.	O
5	O
%	O

Fat	O
-	O
invisible	O
AML	B-DS

>	O
–	O
10	O
HU	O

≥	O
0	O
.	O
71	O

≤	O
16	O
.	O
5	O
%	O

Diagnosis	O

Clinical	O
Presentation	O

The	O
increased	O
use	O
of	O
cross	O
-	O
sectional	O
imaging	O
and	O
advances	O
in	O
imaging	O
technology	O
explain	O
that	O
the	O
majority	O
(>	O
80	O
%)	O
of	O
AMLs	B-DS
are	O
now	O
incidentally	O
found	O
.	O

Most	O
patients	O
are	O
asymptomatic	O
when	O
they	O
receive	O
the	O
diagnosis	O
of	O
an	O
AML	B-DS
[	O
2	O
].	O

Symptomatic	O
presentation	O
is	O
most	O
frequently	O
related	O
to	O
spontaneous	O
retroperitoneal	O
haemorrhage	O
,	O
although	O
this	O
is	O
seen	O
in	O
less	O
than	O
15	O
%	O
of	O
cases	O
[	O
2	O
].	O

This	O
may	O
lead	O
to	O
shock	O
in	O
one	O
-	O
third	O
of	O
patients	O
.	O

Therefore	O
,	O
risk	O
of	O
a	O
life	O
-	O
threatening	O
bleeding	O
is	O
the	O
main	O
clinical	O
concern	O
in	O
a	O
patient	O
diagnosed	O
with	O
AML	B-DS
.	O

Other	O
symptoms	O
and	O
signs	O
include	O
a	O
palpable	O
mass	O
,	O
flank	O
pain	O
,	O
haematuria	O
,	O
anaemia	B-DS
,	O
urinary	B-DS
tract	I-DS
infection	I-DS
,	O
or	O
renal	B-DS
failure	I-DS
[	O
1112	O
].	O

In	O
contrast	O
to	O
the	O
benign	O
prognosis	O
of	O
classic	O
renal	B-DS
AMLs	I-DS
,	O
the	O
epithelioid	O
variant	O
may	O
undergo	O
malignant	O
transformation	O
,	O
although	O
this	O
is	O
rare	O
.	O

This	O
is	O
manifested	O
by	O
local	O
aggressiveness	O
,	O
including	O
lymphadenopathy	B-DS
,	O
and	O
distal	O
metastases	O
.	O

The	O
larger	O
the	O
tumour	O
,	O
the	O
more	O
likely	O
it	O
is	O
to	O
spread	O
[	O
311	O
].	O

In	O
TSC	B-DS
and	O
LAM	B-DS
,	O
the	O
disease	O
process	O
tends	O
to	O
be	O
more	O
aggressive	O
compared	O
to	O
the	O
sporadic	O
form	O
.	O

This	O
implicates	O
that	O
symptomatic	O
presentation	O
is	O
more	O
common	O
in	O
this	O
subgroup	O
[	O
612	O
].	O

In	O
TSC	B-DS
,	O
hamartomas	B-DS
are	O
formed	O
in	O
multiple	O
organs	O
throughout	O
the	O
body	O
,	O
leading	O
to	O
a	O
variety	O
of	O
symptoms	O
.	O

About	O
90	O
%	O
of	O
patients	O
with	O
TSC	B-DS
have	O
skin	O
manifestations	O
,	O
with	O
a	O
range	O
from	O
facial	O
angiofibromas	O
to	O
hypomelanotic	O
macules	O
.	O

Neurological	O
symptoms	O
,	O
including	O
epilepsy	B-DS
,	O
behavioural	B-DS
problems	I-DS
,	O
and	O
cognitive	B-DS
impairment	I-DS
,	O
occur	O
in	O
up	O
to	O
85	O
%	O
of	O
patients	O
.	O

Renal	B-DS
AMLs	I-DS
are	O
present	O
in	O
approximately	O
75	O
%	O
of	O
patients	O
with	O
TSC	B-DS
and	O
manifest	O
as	O
bilateral	O
and	O
multiple	O
tumours	B-DS
,	O
with	O
a	O
high	O
tendency	O
to	O
grow	O
and	O
cause	O
spontaneous	O
bleeding	O
.	O

LAM	B-DS
,	O
in	O
association	O
with	O
TSC	B-DS
or	O
in	O
the	O
sporadic	O
form	O
,	O
is	O
characterised	O
by	O
cystic	O
changes	O
within	O
the	O
lung	O
parenchyma	O
.	O

This	O
may	O
lead	O
to	O
chylous	B-DS
pleural	I-DS
effusions	I-DS
,	O
recurrent	B-DS
pneumothoraces	I-DS
,	O
and	O
cystic	B-DS
lung	I-DS
disease	I-DS
[	O
2678	O
].	O

Imaging	O
Findings	O

Typical	O
renal	B-DS
AML	I-DS
can	O
be	O
diagnosed	O
accurately	O
based	O
on	O
imaging	O
findings	O
.	O

The	O
demonstration	O
of	O
macroscopic	O
fat	O
within	O
a	O
lesion	O
is	O
the	O
hallmark	O
feature	O
on	O
all	O
modalities	O
.	O

However	O
,	O
AML	B-DS
represent	O
a	O
diagnostic	O
challenge	O
for	O
every	O
imaging	O
method	O
in	O
case	O
of	O
haemorrhage	O
,	O
calcification	O
,	O
necrosis	O
,	O
or	O
low	O
fat	O
content	O
.	O

All	O
imaging	O
features	O
of	O
renal	B-DS
AML	I-DS
are	O
summarized	O
in	O
Table	O
2	O
.	O

Imaging	O
features	O
of	O
renal	B-DS
AML	I-DS
[	O
23491011	O
].	O

US	O

UECT	O

MRI	O
-	O
T1	O

MRI	O
-	O
T2	O

MRI	O
-	O
CSI	O


Fat	O
-	O
rich	O
AML	B-DS

Markedly	O
hyperechoic	O

Hypoattenuating	O

Signal	O
loss	O
on	O
FS	O

Hyperintense	O

Decrease	O
in	O
signal	O
intensity	O

Fat	O
-	O
poor	O
AML	B-DS

Slightly	O
hyperechoic	O

Heterogeneously	O
isoattenuating	O
or	O
hyperattenuating	O

+/–	O
signal	O
loss	O
on	O
FS	O

Heterogeneously	O
or	O
homogeneosly	O
hypointense	O

Decrease	O
in	O
signal	O
intensity	O

Fat	O
-	O
invisible	O
AML	B-DS

Isoechoic	O

Homogeneously	O
hyperattenuating	O

No	O
signal	O
loss	O
on	O
FS	O

Homogeneously	O
hypointense	O

No	O
decrease	O
in	O
signal	O
intensity	O

Note	O
:	O
FS	O
=	O
fat	O
suppression	O
;	O
+/–	O
=	O
loss	O
of	O
signal	O
on	O
fat	O
-	O
suppressed	O
MRI	O
may	O
or	O
may	O
not	O
be	O
present	O
.	O

Ultrasound	O

The	O
classical	O
appearance	O
of	O
a	O
fat	O
-	O
rich	O
AML	B-DS
on	O
ultrasound	O
(	O
US	O
)	O
is	O
that	O
of	O
a	O
hyperechoic	O
lesion	O
with	O
a	O
posterior	O
acoustic	O
shadow	O
(	O
Figure	O
1	O
).	O

The	O
hyperechoic	O
nature	O
of	O
a	O
classic	O
AML	B-DS
is	O
the	O
result	O
of	O
the	O
combination	O
of	O
its	O
fat	O
,	O
blood	O
vessel	O
,	O
and	O
muscle	O
contents	O
,	O
while	O
the	O
shadowing	O
is	O
due	O
to	O
the	O
multiple	O
tissue	O
interfaces	O
between	O
those	O
different	O
elements	O
[	O
11	O
].	O

The	O
echogenicity	O
of	O
the	O
mass	O
is	O
the	O
same	O
as	O
or	O
greater	O
than	O
that	O
of	O
the	O
renal	O
sinus	O
[	O
234	O
].	O

However	O
,	O
this	O
hyperechogenicity	O
is	O
not	O
a	O
constant	O
finding	O
.	O

As	O
the	O
amount	O
of	O
fat	O
deceases	O
,	O
the	O
echogenicity	O
of	O
the	O
lesion	O
decreases	O
.	O

Fat	O
-	O
poor	O
AML	B-DS
has	O
a	O
mixed	O
echotexture	O
,	O
being	O
hyperechoic	O
and	O
isoechoic	O
compared	O
with	O
renal	O
parenchyma	O
.	O

Fat	O
-	O
invisible	O
AML	B-DS
is	O
homogenously	O
isoechoic	O
with	O
respect	O
to	O
renal	O
parenchyma	O
.	O

The	O
echogenicity	O
of	O
both	O
tumours	B-DS
is	O
less	O
than	O
that	O
of	O
the	O
renal	O
sinus	O
.	O

It	O
is	O
challenging	O
to	O
differentiate	O
them	O
from	O
other	O
renal	O
lesions	O
such	O
as	O
RCC	B-DS
,	O
which	O
has	O
an	O
echogenicity	O
that	O
is	O
also	O
less	O
than	O
that	O
of	O
the	O
renal	O
sinus	O
[	O
3410	O
].	O

The	O
lack	O
of	O
sensitivity	O
of	O
US	O
at	O
defining	O
small	O
renal	O
masses	O
implicates	O
that	O
the	O
diagnostic	O
reliability	O
of	O
this	O
imaging	O
modality	O
is	O
not	O
high	O
enough	O
to	O
allow	O
it	O
to	O
be	O
used	O
for	O
diagnosing	O
renal	B-DS
AMLs	I-DS
in	O
daily	O
practice	O
[	O
211	O
].	O

Additional	O
imaging	O
studies	O
may	O
be	O
needed	O
to	O
confirm	O
the	O
diagnosis	O
,	O
i	O
.	O
e	O
.	O
the	O
presence	O
of	O
fat	O
.	O

US	O
image	O
showing	O
a	O
fat	O
-	O
rich	O
AML	B-DS
(	O
arrow	O
).	O

The	O
tumour	O
is	O
more	O
hyperechoic	O
than	O
the	O
right	O
renal	O
sinus	O
(	O
asterisk	O
)	O
[	O
10	O
].	O

Computed	O
Tomography	O

The	O
imaged	O
-	O
based	O
detection	O
of	O
fat	O
generally	O
starts	O
with	O
CT	O
.	O

As	O
on	O
US	O
,	O
the	O
characteristics	O
of	O
AMLs	B-DS
on	O
UECT	O
may	O
vary	O
due	O
to	O
variable	O
quantities	O
of	O
angiogenic	O
,	O
myogenic	O
,	O
and	O
fatty	O
elements	O
.	O

The	O
presence	O
of	O
ROIs	O
containing	O
attenuations	O
of	O
–	O
10	O
HU	O
or	O
less	O
is	O
a	O
reliable	O
sign	O
of	O
an	O
area	O
of	O
adipose	O
tissue	O
[	O
34	O
].	O

Therefore	O
,	O
detecting	O
fat	O
is	O
feasible	O
in	O
most	O
fat	O
-	O
rich	O
AMLs	B-DS
(	O
Figure	O
2	O
).	O

However	O
,	O
some	O
fat	O
-	O
rich	O
AMLs	B-DS
contain	O
very	O
small	O
areas	O
of	O
fat	O
,	O
which	O
may	O
not	O
be	O
recognized	O
at	O
CT	O
.	O

Therefore	O
,	O
the	O
acquisition	O
of	O
thin	O
slice	O
sections	O
(	O
1	O
.	O
5	O
–	O
3	O
.	O
0	O
mm	O
)	O
and	O
obtaining	O
attenuation	O
measurements	O
using	O
small	O
ROIs	O
or	O
even	O
pixel	O
values	O
may	O
be	O
needed	O
.	O

Several	O
authors	O
reported	O
a	O
higher	O
sensitivity	O
for	O
detecting	O
small	O
foci	O
of	O
fat	O
when	O
using	O
pixel	O
mapping	O
,	O
using	O
a	O
line	O
or	O
square	O
of	O
four	O
pixels	O
.	O

In	O
fat	O
-	O
poor	O
AMLs	B-DS
,	O
UECT	O
cannot	O
show	O
a	O
hypoattenuating	O
area	O
measuring	O
less	O
than	O
–	O
10	O
HU	O
.	O

The	O
attenuation	O
values	O
of	O
such	O
lesions	O
range	O
widely	O
,	O
according	O
to	O
the	O
size	O
or	O
location	O
of	O
a	O
ROI	O
:	O
when	O
a	O
ROI	O
is	O
placed	O
in	O
a	O
region	O
of	O
muscle	O
cells	O
and	O
vessels	O
,	O
the	O
lesion	O
attenuation	O
will	O
be	O
higher	O
than	O
when	O
a	O
ROI	O
is	O
placed	O
in	O
an	O
area	O
that	O
consists	O
mostly	O
of	O
fat	O
cells	O
.	O

For	O
this	O
reason	O
,	O
fat	O
-	O
poor	O
AMLs	B-DS
are	O
heterogeneously	O
isoattenuating	O
or	O
hyperattenuating	O
.	O

On	O
the	O
contrary	O
,	O
fat	O
-	O
invisible	O
AMLs	B-DS
appear	O
homogenously	O
hyperattenuating	O
(	O
Figure	O
3	O
).	O

Because	O
they	O
contain	O
too	O
little	O
fat	O
cells	O
,	O
UECT	O
is	O
not	O
able	O
to	O
show	O
any	O
fat	O
attenuation	O
in	O
these	O
lesions	O
.	O

So	O
wherever	O
a	O
ROI	O
is	O
placed	O
in	O
fat	O
-	O
invisible	O
AMLs	B-DS
,	O
their	O
attenuation	O
numbers	O
tend	O
to	O
be	O
higher	O
and	O
fairly	O
constant	O
compared	O
with	O
those	O
of	O
fat	O
-	O
poor	O
AMLs	B-DS
[	O
91011	O
].	O

UECT	O
showing	O
bilateral	O
and	O
multiple	O
AMLs	B-DS
in	O
a	O
patient	O
with	O
TSC	B-DS
.	O

Each	O
lesion	O
contains	O
attenuation	O
numbers	O
less	O
than	O
–	O
10	O
HU	O
,	O
consistent	O
with	O
fat	O
-	O
rich	O
AML	B-DS
[	O
3	O
].	O

UECT	O
demonstrating	O
a	O
left	O
solid	O
renal	O
lesion	O
(	O
arrow	O
).	O

It	O
appears	O
homogeneously	O
hyperdense	O
and	O
has	O
attenuation	O
values	O
as	O
high	O
as	O
44	O
HU	O
,	O
consistent	O
with	O
fat	O
-	O
invisible	O
AML	B-DS
[	O
9	O
].	O

There	O
are	O
several	O
other	O
variants	O
in	O
which	O
an	O
AML	B-DS
can	O
appear	O
on	O
UECT	O
.	O

Frequently	O
,	O
a	O
perirenal	O
or	O
intratumoural	O
haemorrhage	O
is	O
present	O
(	O
Figure	O
4	O
).	O

This	O
hyperdense	O
collection	O
may	O
obscure	O
the	O
fat	O
,	O
leading	O
to	O
misdiagnosing	O
a	O
simple	O
AML	B-DS
as	O
a	O
renal	B-DS
cancer	I-DS
[	O
2	O
].	O

Lesions	O
that	O
contain	O
fat	O
and	O
calcifications	O
also	O
represent	O
a	O
diagnostic	O
challenge	O
.	O

As	O
the	O
presence	O
of	O
adipose	O
tissue	O
is	O
highly	O
suggestive	O
of	O
AML	B-DS
,	O
the	O
presence	O
of	O
calcification	O
raises	O
the	O
possibility	O
of	O
renal	B-DS
cancer	I-DS
.	O

However	O
,	O
several	O
authors	O
reported	O
the	O
existence	O
of	O
both	O
AMLs	B-DS
with	O
calcification	O
and	O
RCCs	O
having	O
fat	O
without	O
calcification	O
[	O
111314	O
].	O

Another	O
,	O
less	O
frequent	O
appearance	O
is	O
that	O
of	O
necrosis	O
within	O
a	O
lesion	O
,	O
being	O
rather	O
typical	O
for	O
epithelioid	O
AMLs	B-DS
[	O
34	O
].	O

Contrast	O
-	O
enhanced	O
CT	O
showing	O
two	O
features	O
:	O
a	O
perirenal	O
hematoma	O
and	O
enhancing	O
lesion	O
with	O
aneurysm	B-DS
formation	O
(	O
arrowhead	O
)	O
and	O
a	O
thrombus	B-DS
in	O
the	O
IVC	O
(	O
arrow	O
)	O
[	O
15	O
].	O

Contrast	O
-	O
enhanced	O
CT	O
is	O
not	O
routinely	O
indicated	O
in	O
diagnosing	O
renal	B-DS
AMLs	I-DS
,	O
but	O
should	O
be	O
performed	O
in	O
selected	O
cases	O
.	O

Frequently	O
,	O
large	O
AMLs	B-DS
contain	O
dilated	O
blood	O
vessels	O
that	O
have	O
the	O
potential	O
of	O
rupturing	O
and	O
bleeding	O
.	O

Whenever	O
tumour	O
bleeding	O
is	O
suspected	O
,	O
it	O
is	O
essential	O
to	O
identify	O
the	O
tortuous	O
vessels	O
using	O
contrast	O
-	O
enhanced	O
CT	O
,	O
before	O
therapeutic	O
embolization	O
can	O
be	O
scheduled	O
[	O
1015	O
].	O

Magnetic	O
Resonance	O
Imaging	O

In	O
the	O
diagnosis	O
of	O
AML	B-DS
,	O
MRI	O
is	O
equivalent	O
in	O
accuracy	O
to	O
CT	O
.	O

Several	O
MRI	O
sequences	O
can	O
be	O
used	O
.	O

The	O
classical	O
approach	O
is	O
to	O
locate	O
fat	O
within	O
a	O
mass	O
by	O
comparing	O
T1	O
-	O
weighted	O
images	O
with	O
and	O
without	O
frequency	O
selective	O
fat	O
suppression	O
.	O

A	O
classic	O
fat	O
-	O
rich	O
AML	B-DS
appears	O
T1	O
-	O
hypointense	O
with	O
and	O
T1	O
-	O
hyperintense	O
without	O
fat	O
suppression	O
[	O
234	O
].	O

However	O
,	O
this	O
T1	O
-	O
hyperintensity	O
is	O
not	O
a	O
specific	O
characteristic	O
of	O
AML	B-DS
and	O
can	O
also	O
be	O
present	O
in	O
RCC	B-DS
and	O
haemorrhagic	O
cysts	O
.	O

Moreover	O
,	O
fat	O
-	O
invisible	O
AMLs	B-DS
contain	O
too	O
little	O
fat	O
to	O
show	O
any	O
hypointensity	O
on	O
fat	O
-	O
suppressed	O
T1	O
-	O
weighted	O
images	O
.	O

In	O
such	O
cases	O
,	O
other	O
techniques	O
may	O
help	O
in	O
differentiating	O
between	O
those	O
entities	O
[	O
1116	O
].	O

More	O
recently	O
,	O
the	O
application	O
of	O
MRI	O
artefacts	O
has	O
been	O
suggested	O
to	O
evaluate	O
fat	O
in	O
renal	B-DS
tumours	I-DS
.	O

One	O
of	O
them	O
,	O
the	O
chemical	O
shift	O
artefact	O
,	O
is	O
due	O
to	O
the	O
differences	O
between	O
resonance	O
frequencies	O
of	O
fat	O
and	O
water	O
.	O

This	O
results	O
in	O
alternating	O
high	O
and	O
low	O
signals	O
in	O
the	O
frequency	O
encoding	O
direction	O
on	O
opposed	O
-	O
phase	O
imaging	O
.	O

This	O
out	O
-	O
of	O
-	O
phase	O
cancellation	O
effect	O
between	O
fat	O
and	O
water	O
gives	O
rise	O
to	O
another	O
MRI	O
artefact	O
,	O
called	O
the	O
black	O
boundary	O
or	O
India	O
ink	O
artefact	O
.	O

This	O
artificially	O
created	O
black	O
line	O
is	O
located	O
at	O
the	O
junction	O
of	O
fat	O
(	O
present	O
in	O
AML	B-DS
cells	O
)	O
and	O
water	O
(	O
present	O
in	O
renal	O
parenchyma	O
)	O
and	O
results	O
in	O
a	O
sharp	O
delineation	O
of	O
the	O
muscle	O
-	O
fat	O
boundary	O
(	O
Figure	O
5	O
).	O

This	O
sign	O
is	O
indicative	O
of	O
an	O
AML	B-DS
[	O
341116	O
].	O

It	O
is	O
especially	O
useful	O
in	O
fat	O
-	O
poor	O
AMLs	B-DS
and	O
very	O
small	O
lesions	O
,	O
in	O
which	O
the	O
typical	O
T1	O
features	O
may	O
not	O
be	O
noticeable	O
[	O
2	O
].	O

However	O
,	O
fat	O
-	O
invisible	O
AMLs	B-DS
do	O
not	O
show	O
this	O
decrease	O
in	O
signal	O
intensity	O
,	O
because	O
they	O
contain	O
too	O
little	O
fat	O
cells	O
[	O
10	O
].	O

Opposed	O
-	O
phase	O
T1	O
-	O
weighted	O
MR	O
image	O
with	O
a	O
hyperintense	O
renal	O
mass	O
.	O

The	O
India	O
ink	O
artefact	O
(	O
arrow	O
)	O
is	O
present	O
at	O
the	O
interface	O
of	O
the	O
lesion	O
with	O
the	O
kidney	O
[	O
16	O
].	O

T2	O
-	O
weighted	O
images	O
can	O
also	O
be	O
used	O
for	O
diagnosing	O
AML	B-DS
.	O

Fat	O
-	O
rich	O
AML	B-DS
typically	O
is	O
hyperintense	O
with	O
respect	O
to	O
renal	O
parenchyma	O
.	O

It	O
has	O
hyperintense	O
foci	O
within	O
a	O
hypointense	O
background	O
,	O
because	O
areas	O
of	O
fat	O
are	O
distributed	O
among	O
blood	O
vessels	O
and	O
muscle	O
cells	O
.	O

Fat	O
-	O
poor	O
AML	B-DS
is	O
either	O
homogeneous	O
or	O
heterogeneous	O
hypointense	O
compared	O
with	O
renal	O
tissue	O
,	O
depending	O
on	O
the	O
distribution	O
of	O
its	O
areas	O
of	O
fat	O
.	O

If	O
these	O
areas	O
are	O
small	O
but	O
diffuse	O
,	O
the	O
signal	O
intensity	O
is	O
homogeneous	O
,	O
while	O
it	O
is	O
heterogeneous	O
when	O
fat	O
cells	O
are	O
located	O
focal	O
.	O

Finally	O
,	O
fat	O
-	O
invisible	O
AML	B-DS
is	O
homogeneously	O
hypointense	O
in	O
comparison	O
to	O
renal	O
parenchyma	O
on	O
T2	O
,	O
because	O
of	O
the	O
dominance	O
of	O
the	O
muscle	O
component	O
and	O
the	O
paucity	O
of	O
adipose	O
tissue	O
[	O
23410	O
].	O

Contrast	O
-	O
enhanced	O
MRI	O
has	O
a	O
limited	O
role	O
in	O
the	O
diagnosis	O
of	O
AML	B-DS
.	O

After	O
intravenous	O
administration	O
of	O
gadolinium	O
,	O
renal	B-DS
AMLs	I-DS
show	O
hypointense	O
compared	O
to	O
renal	O
parenchyma	O
.	O

However	O
,	O
these	O
enhancement	O
characteristics	O
appear	O
to	O
be	O
similar	O
to	O
those	O
of	O
hypovascular	O
RCCs	O
[	O
1117	O
].	O

Percutaneous	O
Biopsy	O

Most	O
AMLs	B-DS
can	O
be	O
diagnosed	O
with	O
imaging	O
by	O
identifying	O
intralesional	O
fat	O
.	O

However	O
,	O
in	O
select	O
cases	O
,	O
the	O
use	O
of	O
imaging	O
alone	O
is	O
insufficient	O
and	O
percutaneous	O
renal	O
biopsy	O
may	O
be	O
necessary	O
for	O
correctly	O
diagnosing	O
the	O
renal	O
mass	O
,	O
thus	O
avoiding	O
unnecessary	O
treatment	O
.	O

Nowadays	O
,	O
percutaneous	O
biopsy	O
is	O
increasingly	O
used	O
to	O
differentiate	O
between	O
benign	O
and	O
malignant	O
renal	O
lesions	O
[	O
1819	O
].	O

Currently	O
,	O
percutaneous	O
renal	O
biopsy	O
is	O
recommended	O
only	O
for	O
differentiating	O
fat	O
-	O
invisible	O
AML	B-DS
from	O
RCC	B-DS
,	O
if	O
both	O
CT	O
and	O
MR	O
images	O
are	O
inconclusive	O
.	O

A	O
fat	O
-	O
invisible	O
AML	B-DS
typically	O
appears	O
as	O
a	O
hyperattenuating	O
mass	O
that	O
enhance	O
homogenously	O
on	O
UECT	O
.	O

Although	O
this	O
presentation	O
is	O
uncommon	O
for	O
a	O
RCC	B-DS
,	O
both	O
pathologies	O
may	O
appear	O
identical	O
on	O
imaging	O
.	O

In	O
these	O
cases	O
,	O
the	O
mass	O
should	O
be	O
evaluated	O
with	O
MRI	O
.	O

While	O
a	O
fat	O
-	O
invisible	O
AML	B-DS
is	O
homogenously	O
hypointense	O
on	O
T2	O
-	O
weighted	O
MR	O
images	O
,	O
clear	O
cell	O
RCC	B-DS
appears	O
hyperintense	O
[	O
9	O
].	O

However	O
,	O
the	O
papillary	O
subtype	O
of	O
RCC	B-DS
appears	O
also	O
hypointense	O
.	O

Therefore	O
,	O
percutaneous	O
biopsy	O
is	O
required	O
to	O
differentiate	O
fat	O
-	O
invisible	O
AML	B-DS
and	O
papillary	O
RCC	B-DS
when	O
a	O
small	O
(	O
less	O
than	O
3	O
cm	O
),	O
T2	O
-	O
hypointense	O
renal	O
mass	O
without	O
evidence	O
of	O
intratumoural	O
fat	O
is	O
encountered	O
[	O
18	O
].	O

If	O
the	O
lesion	O
is	O
larger	O
(	O
more	O
than	O
3	O
cm	O
)	O
or	O
if	O
there	O
is	O
evidence	O
of	O
haemorrhage	O
,	O
percutaneous	O
biopsy	O
may	O
be	O
skipped	O
.	O

Proceeding	O
directly	O
to	O
a	O
suitable	O
treatment	O
may	O
be	O
a	O
more	O
appropriate	O
option	O
,	O
both	O
to	O
avoid	O
further	O
bleeding	O
and	O
because	O
epithelioid	O
AML	B-DS
and	O
RCC	B-DS
are	O
more	O
presumable	O
[	O
3	O
].	O

Differential	O
Diagnosis	O

Over	O
the	O
last	O
decades	O
,	O
the	O
detection	O
of	O
small	O
renal	O
masses	O
definitely	O
increased	O
by	O
the	O
increased	O
use	O
of	O
cross	O
-	O
sectional	O
imaging	O
studies	O
.	O

A	O
lot	O
of	O
these	O
incidentally	O
found	O
renal	O
lesions	O
are	O
usually	O
presumed	O
to	O
be	O
RCC	B-DS
and	O
are	O
treated	O
as	O
such	O
.	O

However	O
,	O
a	O
recent	O
study	O
showed	O
that	O
21	O
.	O
5	O
%	O
of	O
those	O
lesions	O
turned	O
out	O
to	O
be	O
benign	O
after	O
surgery	O
.	O

AML	B-DS
accounted	O
for	O
nearly	O
half	O
of	O
this	O
group	O
of	O
benign	O
masses	O
.	O

This	O
shows	O
that	O
the	O
differentiation	O
between	O
AML	B-DS
and	O
RCC	B-DS
remains	O
difficult	O
in	O
routine	O
practice	O
[	O
202122	O
].	O

As	O
already	O
repeatedly	O
stated	O
above	O
,	O
classic	O
AML	B-DS
can	O
be	O
distinguished	O
from	O
RCC	B-DS
by	O
the	O
presence	O
of	O
macroscopic	O
fat	O
in	O
sufficient	O
quantity	O
to	O
be	O
detected	O
on	O
UECT	O
.	O

However	O
,	O
in	O
4	O
–	O
5	O
%	O
of	O
AML	B-DS
cases	O
,	O
no	O
fat	O
can	O
be	O
visualized	O
on	O
CT	O
,	O
increasing	O
the	O
difficulty	O
in	O
differentiating	O
it	O
from	O
RCC	B-DS
.	O

Correctly	O
diagnosing	O
this	O
fat	O
-	O
poor	O
and	O
fat	O
-	O
invisible	O
AML	B-DS
requires	O
sufficient	O
clinical	O
and	O
imaging	O
information	O
.	O

Clinical	O
information	O
supporting	O
a	O
diagnosis	O
of	O
AML	B-DS
includes	O
a	O
younger	O
age	O
,	O
female	O
sex	O
,	O
and	O
asymptomatic	O
presentation	O
.	O

Imaging	O
findings	O
that	O
should	O
raise	O
the	O
suspicion	O
of	O
AML	B-DS
include	O
the	O
absence	O
of	O
calcification	O
,	O
the	O
absence	O
of	O
perinephric	O
collateral	O
vessels	O
,	O
multiple	O
lesions	O
,	O
hyperattenuation	O
in	O
comparison	O
to	O
renal	O
parenchyma	O
on	O
UECT	O
,	O
and	O
hypointensity	O
on	O
T2	O
-	O
weighted	O
MRI	O
.	O

However	O
,	O
because	O
these	O
characteristic	O
features	O
are	O
not	O
present	O
in	O
every	O
AML	B-DS
and	O
exceptions	O
do	O
exist	O
,	O
no	O
single	O
finding	O
or	O
modality	O
is	O
perfectly	O
accurate	O
[	O
2021222324	O
].	O

Treatment	O

As	O
most	O
renal	B-DS
AMLs	I-DS
are	O
diagnosed	O
incidentally	O
in	O
asymptomatic	O
patients	O
,	O
therapeutic	O
interventions	O
are	O
required	O
in	O
a	O
minority	O
of	O
patients	O
.	O

Potential	O
interventions	O
include	O
selective	O
renal	O
artery	O
embolization	O
,	O
nephron	O
-	O
sparing	O
surgery	O
,	O
complete	O
nephrectomy	O
,	O
cryo	O
-	O
and	O
radiofrequency	O
ablation	O
,	O
and	O
treatment	O
with	O
mTOR	B-GP
inhibitors	O
.	O

Indications	O

Historically	O
,	O
the	O
main	O
indications	O
for	O
intervention	O
have	O
been	O
the	O
presence	O
of	O
symptoms	O
,	O
the	O
presence	O
in	O
women	O
of	O
childbearing	O
age	O
,	O
suspicion	O
of	O
malignancy	O
,	O
and	O
size	O
larger	O
than	O
4	O
cm	O
.	O

The	O
use	O
of	O
a	O
4	O
cm	O
tumour	O
size	O
as	O
a	O
criterion	O
for	O
treatment	O
comes	O
from	O
a	O
frequently	O
quoted	O
review	O
published	O
in	O
1986	O
[	O
21119	O
].	O

The	O
authors	O
of	O
this	O
review	O
reported	O
that	O
82	O
%	O
of	O
patients	O
with	O
renal	B-DS
AMLs	I-DS
larger	O
than	O
4	O
cm	O
experienced	O
symptoms	O
and	O
51	O
%	O
of	O
them	O
presented	O
with	O
active	O
retroperitoneal	O
haemorrhage	O
.	O

Other	O
early	O
series	O
showed	O
that	O
patients	O
with	O
tumours	B-DS
larger	O
than	O
4	O
cm	O
had	O
interval	O
growth	O
and	O
needed	O
treatment	O
more	O
often	O
.	O

They	O
all	O
suggested	O
4	O
cm	O
as	O
the	O
limit	O
above	O
which	O
an	O
intervention	O
should	O
be	O
considered	O
.	O

This	O
threshold	O
has	O
been	O
widely	O
adopted	O
for	O
many	O
years	O
,	O
although	O
the	O
understanding	O
of	O
the	O
biology	O
and	O
management	O
of	O
the	O
disease	O
have	O
changed	O
significantly	O
since	O
then	O
[	O
252627	O
].	O

However	O
,	O
this	O
threshold	O
has	O
recently	O
been	O
questioned	O
.	O

Recent	O
studies	O
do	O
not	O
support	O
the	O
4	O
cm	O
size	O
criterion	O
.	O

One	O
author	O
found	O
that	O
only	O
30	O
%	O
of	O
AMLs	B-DS
larger	O
than	O
4	O
cm	O
were	O
symptomatic	O
[	O
2	O
].	O

Another	O
one	O
showed	O
that	O
using	O
a	O
cut	O
-	O
off	O
of	O
4	O
cm	O
as	O
predictor	O
of	O
haemorrhage	O
has	O
a	O
lower	O
specificity	O
than	O
an	O
aneurysm	B-DS
size	O
of	O
5	O
mm	O
.	O

In	O
other	O
series	O
,	O
the	O
angiographic	O
appearance	O
of	O
AMLs	B-DS
was	O
used	O
for	O
analysing	O
them	O
.	O

They	O
found	O
that	O
lesions	O
with	O
high	O
vascularity	O
(	O
multiple	O
,	O
large	O
,	O
tortuous	O
vessels	O
)	O
were	O
more	O
likely	O
to	O
require	O
intervention	O
for	O
bleeding	O
.	O

All	O
this	O
evidence	O
would	O
suggest	O
that	O
,	O
although	O
tumour	O
diameter	O
is	O
important	O
,	O
the	O
size	O
of	O
related	O
aneurysms	B-DS
and	O
the	O
vascularity	O
of	O
the	O
AML	B-DS
may	O
ultimately	O
be	O
more	O
significant	O
[	O
1127	O
].	O

As	O
most	O
AMLs	B-DS
now	O
are	O
found	O
incidentally	O
,	O
physicians	O
are	O
challenged	O
by	O
a	O
treatment	O
dilemma	O
when	O
an	O
AML	B-DS
in	O
an	O
asymptomatic	O
patient	O
reaches	O
the	O
4	O
-	O
cm	O
threshold	O
.	O

They	O
are	O
worried	O
that	O
these	O
“	O
large	O
”	O
lesions	O
may	O
rupture	O
and	O
cause	O
life	O
-	O
threatening	O
bleeding	O
.	O

Consequently	O
,	O
AMLs	B-DS
are	O
often	O
imaged	O
intensively	O
and	O
repeatedly	O
,	O
and	O
treated	O
empirically	O
once	O
they	O
attain	O
a	O
diameter	O
of	O
4	O
cm	O
[	O
26	O
].	O

The	O
current	O
guidelines	O
of	O
the	O
European	O
Association	O
of	O
Urology	O
recommend	O
intervention	O
in	O
well	O
-	O
selected	O
cases	O
,	O
including	O
symptomatic	O
tumours	B-DS
,	O
large	O
lesions	O
,	O
presence	O
in	O
women	O
of	O
childbearing	O
age	O
,	O
and	O
poor	O
access	O
to	O
follow	O
-	O
up	O
or	O
emergency	O
care	O
.	O

A	O
size	O
threshold	O
for	O
treatment	O
,	O
however	O
,	O
remains	O
controversial	O
[	O
2242526	O
].	O

Active	O
Surveillance	O

Once	O
the	O
initial	O
diagnostic	O
evaluations	O
are	O
completed	O
and	O
indications	O
for	O
treatment	O
are	O
not	O
present	O
,	O
active	O
surveillance	O
should	O
be	O
used	O
to	O
monitor	O
progression	O
of	O
known	O
tumours	B-DS
and	O
development	O
of	O
new	O
ones	O
[	O
29	O
].	O

For	O
sporadic	O
AML	B-DS
,	O
there	O
are	O
currently	O
no	O
guidelines	O
on	O
the	O
frequency	O
of	O
imaging	O
studies	O
neither	O
on	O
which	O
modality	O
should	O
be	O
used	O
.	O

These	O
decisions	O
are	O
likely	O
to	O
be	O
institution	O
dependent	O
and	O
should	O
be	O
guided	O
by	O
the	O
individual	O
clinical	O
scenario	O
[	O
2	O
].	O

Annual	O
repeat	O
of	O
imaging	O
seems	O
to	O
be	O
appropriate	O
for	O
small	O
,	O
solitary	O
lesions	O
.	O

For	O
hereditary	O
AML	B-DS
,	O
the	O
International	O
Tuberous	B-DS
Sclerosis	I-DS
Complex	O
Consensus	O
recommends	O
the	O
use	O
of	O
MRI	O
,	O
because	O
of	O
its	O
increased	O
sensitivity	O
in	O
the	O
detection	O
of	O
adipose	O
tissue	O
.	O

Annual	O
clinical	O
evaluation	O
of	O
renal	O
function	O
and	O
blood	O
pressure	O
is	O
also	O
required	O
in	O
these	O
cases	O
[	O
192830	O
].	O

Embolization	O

Historically	O
,	O
there	O
was	O
a	O
greater	O
tendency	O
towards	O
surgery	O
in	O
the	O
treatment	O
of	O
renal	B-DS
AMLs	I-DS
.	O

They	O
were	O
often	O
excised	O
because	O
malignancy	O
could	O
not	O
be	O
excluded	O
.	O

However	O
,	O
this	O
has	O
shifted	O
,	O
as	O
AMLs	B-DS
can	O
now	O
be	O
confidently	O
recognized	O
at	O
imaging	O
.	O

Selective	O
transarterial	O
embolization	O
is	O
now	O
the	O
first	O
-	O
line	O
treatment	O
option	O
,	O
especially	O
in	O
the	O
event	O
of	O
acute	O
bleeding	O
or	O
hemodynamic	O
instability	O
[	O
25	O
].	O

Many	O
clinicians	O
favour	O
embolization	O
and	O
reserve	O
surgery	O
for	O
patients	O
with	O
uncontrollable	O
symptoms	O
,	O
vascular	B-DS
malformations	I-DS
,	O
failure	O
of	O
embolization	O
,	O
and	O
rare	O
diagnostic	O
uncertainty	O
.	O

When	O
surgery	O
needs	O
to	O
be	O
performed	O
,	O
preoperative	O
embolization	O
of	O
the	O
lesion	O
may	O
be	O
taken	O
into	O
consideration	O
in	O
reducing	O
the	O
difficulty	O
and	O
complications	O
of	O
tumourectomy	O
or	O
nephrectomy	O
[	O
11192732	O
].	O

Embolization	O
is	O
associated	O
with	O
a	O
relatively	O
high	O
percentage	O
of	O
side	O
effects	O
(	O
42	O
.	O
8	O
%),	O
although	O
most	O
of	O
these	O
are	O
post	O
-	O
embolization	O
syndromes	O
.	O

This	O
self	O
-	O
limiting	O
condition	O
is	O
characterized	O
by	O
fever	O
,	O
flank	O
pain	O
,	O
leucocytosis	B-DS
,	O
nausea	O
,	O
and	O
vomiting	O
within	O
the	O
first	O
three	O
days	O
after	O
the	O
procedure	O
,	O
and	O
it	O
is	O
managed	O
conservatively	O
with	O
standard	O
supportive	O
care	O
.	O

Routine	O
prophylaxis	O
,	O
including	O
antipyretics	O
,	O
antiemetics	O
and	O
analgesia	O
,	O
may	O
play	O
a	O
role	O
in	O
periprocedural	O
management	O
[	O
227	O
].	O

Other	O
complications	O
,	O
including	O
non	O
-	O
target	O
embolization	O
of	O
normal	O
parenchyma	O
or	O
renal	B-DS
infarction	I-DS
with	O
abscess	B-DS
forming	O
,	O
are	O
uncommon	O
[	O
111932	O
].	O

In	O
general	O
though	O
,	O
arterial	O
embolization	O
is	O
a	O
well	O
-	O
tolerated	O
procedure	O
.	O

Although	O
it	O
is	O
now	O
seen	O
as	O
the	O
first	O
-	O
line	O
treatment	O
for	O
patients	O
with	O
AMLs	B-DS
,	O
both	O
regrowth	O
and	O
repeated	O
haemorrhage	O
after	O
embolization	O
remain	O
a	O
concern	O
.	O

The	O
effect	O
of	O
embolization	O
may	O
vary	O
,	O
because	O
of	O
the	O
varying	O
amounts	O
of	O
adipose	O
,	O
vascular	O
,	O
and	O
smooth	O
muscle	O
tissue	O
in	O
the	O
lesions	O
.	O

Different	O
authors	O
showed	O
in	O
their	O
series	O
a	O
need	O
for	O
reembolization	O
varying	O
from	O
17	O
%	O
till	O
37	O
%	O
[	O
323334	O
].	O

Surgery	O

Surgical	O
excision	O
in	O
the	O
form	O
of	O
partial	O
or	O
radical	O
nephrectomy	O
is	O
the	O
only	O
treatment	O
that	O
completely	O
removes	O
the	O
renal	O
mass	O
,	O
although	O
recurrence	O
from	O
other	O
parts	O
of	O
the	O
kidney	O
may	O
occur	O
.	O

Every	O
surgery	O
should	O
rely	O
on	O
a	O
nephron	O
sparing	O
approach	O
whenever	O
possible	O
[	O
25	O
].	O

Parenchymal	O
preservation	O
is	O
even	O
more	O
important	O
in	O
patients	O
with	O
TSC	B-DS
or	O
LAM	B-DS
,	O
because	O
of	O
the	O
multifocal	O
disease	O
pattern	O
and	O
the	O
higher	O
recurrence	O
rate	O
.	O

Nephrectomy	O
is	O
indicated	O
only	O
when	O
a	O
renal	B-DS
AML	I-DS
is	O
very	O
large	O
,	O
when	O
suspicion	O
of	O
malignancy	O
is	O
high	O
,	O
and	O
when	O
other	O
treatment	O
options	O
cannot	O
be	O
performed	O
.	O

However	O
,	O
in	O
an	O
emergency	O
setting	O
,	O
a	O
nephrectomy	O
can	O
be	O
lifesaving	O
[	O
3132	O
].	O

Ablation	O

When	O
comparing	O
current	O
treatment	O
methods	O
,	O
cryoablation	O
and	O
percutaneous	O
radiofrequency	O
ablation	O
appear	O
to	O
be	O
attractive	O
alternatives	O
to	O
embolization	O
or	O
surgery	O
.	O

Different	O
series	O
demonstrate	O
good	O
efficacy	O
with	O
minimal	O
complications	O
,	O
few	O
repeat	O
treatments	O
,	O
and	O
no	O
recurrences	O
.	O

However	O
,	O
reports	O
of	O
the	O
use	O
of	O
these	O
minimal	O
invasive	O
techniques	O
are	O
confined	O
to	O
small	O
and	O
asymptomatic	O
lesions	O
[	O
19	O
].	O

Little	O
evidence	O
is	O
available	O
on	O
the	O
application	O
in	O
larger	O
or	O
symptomatic	O
tumours	B-DS
.	O

Overall	O
,	O
ablation	O
has	O
shown	O
some	O
promise	O
in	O
the	O
treatment	O
of	O
a	O
specific	O
AML	B-DS
group	O
that	O
some	O
would	O
say	O
should	O
be	O
managed	O
by	O
active	O
surveillance	O
[	O
23334	O
].	O

Drugs	O

The	O
identification	O
of	O
mutations	O
in	O
TSC1	B-GP
and	O
TSC2	B-GP
and	O
the	O
existence	O
of	O
a	O
licensed	O
drug	O
targeting	O
the	O
mTOR	B-GP
pathway	O
,	O
lead	O
to	O
rapid	O
translation	O
of	O
mTOR	B-GP
inhibitors	O
to	O
patients	O
with	O
TSC	B-DS
and	O
LAM	B-DS
.	O

These	O
medicines	O
interrupt	O
further	O
tumour	O
progression	O
and	O
promote	O
reversion	O
of	O
existing	O
lesions	O
.	O

Sirolimus	O
,	O
also	O
known	O
as	O
rapamycin	O
,	O
was	O
the	O
first	O
mTOR	B-GP
inhibitor	O
analysed	O
in	O
treating	O
hereditary	O
AML	B-DS
.	O

It	O
was	O
originally	O
developed	O
as	O
immunosuppressant	O
for	O
use	O
in	O
organ	O
transplantation	O
.	O

Overall	O
,	O
sirolimus	O
was	O
well	O
tolerated	O
in	O
these	O
early	O
studies	O
,	O
with	O
mouth	B-DS
ulcers	I-DS
,	O
skin	O
lesions	O
,	O
dyslipidaemia	B-DS
,	O
and	O
proteinuria	B-DS
as	O
most	O
commonly	O
encountered	O
side	O
effects	O
.	O

It	O
is	O
now	O
approved	O
for	O
treatment	O
of	O
LAM	B-DS
[	O
6	O
].	O

Everolimus	O
,	O
another	O
mTOR	B-GP
inhibitor	O
and	O
rapamycine	O
derivative	O
,	O
has	O
been	O
studied	O
the	O
most	O
.	O

Currently	O
,	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
European	O
Medicines	O
Agency	O
approve	O
this	O
agent	O
for	O
treating	O
AML	B-DS
in	O
the	O
setting	O
of	O
TSC	B-DS
[	O
323536	O
].	O

The	O
position	O
of	O
mTOR	B-GP
inhibitors	O
in	O
the	O
management	O
of	O
sporadic	O
AML	B-DS
still	O
remains	O
to	O
be	O
determined	O
[	O
2	O
].	O

For	O
asymptomatic	O
AMLs	B-DS
in	O
TSC	B-DS
and	O
LAM	B-DS
that	O
are	O
enlarging	O
and	O
larger	O
than	O
3	O
cm	O
,	O
recent	O
guidelines	O
suggest	O
that	O
mTOR	B-GP
inhibition	O
currently	O
is	O
the	O
most	O
effective	O
first	O
-	O
line	O
treatment	O
.	O

The	O
demonstrated	O
tolerability	O
so	O
far	O
to	O
date	O
is	O
superior	O
to	O
the	O
renal	B-DS
impairment	I-DS
caused	O
by	O
AML	B-DS
progression	O
and	O
is	O
preferable	O
to	O
other	O
treatment	O
modalities	O
[	O
28	O
].	O

Another	O
concern	O
for	O
treating	O
physicians	O
is	O
how	O
long	O
the	O
treatment	O
with	O
those	O
drugs	O
should	O
continue	O
,	O
as	O
the	O
effect	O
of	O
mTOR	B-GP
inhibition	O
is	O
reversible	O
.	O

To	O
continue	O
the	O
treatment	O
for	O
AML	B-DS
,	O
consideration	O
should	O
be	O
given	O
to	O
long	O
-	O
term	O
complications	O
,	O
cost	O
,	O
and	O
safety	O
,	O
compared	O
with	O
other	O
treatment	O
options	O
[	O
3236	O
].	O

Conclusion	O

Renal	B-DS
AML	I-DS
is	O
the	O
most	O
prevalent	O
benign	B-DS
neoplasm	I-DS
of	I-DS
the	I-DS
kidney	I-DS
.	O

It	O
has	O
a	O
variable	O
and	O
heterogeneous	O
nature	O
,	O
with	O
the	O
potential	O
to	O
pose	O
serious	O
diagnostic	O
challenges	O
in	O
clinical	O
practice	O
.	O

The	O
characteristics	O
of	O
classic	O
AMLs	B-DS
are	O
well	O
described	O
,	O
but	O
the	O
radiological	O
distinction	O
between	O
non	O
-	O
classic	O
AMLs	B-DS
and	O
RCCs	O
continues	O
to	O
be	O
difficult	O
.	O

Knowledge	O
of	O
the	O
different	O
types	O
,	O
their	O
classification	O
,	O
and	O
their	O
radiologic	O
appearance	O
will	O
help	O
radiologists	O
in	O
making	O
a	O
correct	O
diagnosis	O
.	O

When	O
an	O
AML	B-DS
is	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
a	O
renal	O
lesion	O
that	O
does	O
not	O
demonstrate	O
classical	O
features	O
,	O
confirmatory	O
imaging	O
,	O
percutaneous	O
renal	O
biopsy	O
,	O
or	O
surgical	O
excision	O
should	O
be	O
performed	O
.	O

Several	O
invasive	O
,	O
non	O
-	O
invasive	O
,	O
and	O
pharmacologic	O
treatment	O
options	O
exist	O
.	O

Careful	O
surveillance	O
before	O
and	O
after	O
treatment	O
is	O
necessary	O
,	O
particularly	O
for	O
patients	O
with	O
TSC	B-DS
or	O
LAM	B-DS
.	O

Without	O
proper	O
management	O
,	O
renal	B-DS
AML	I-DS
may	O
have	O
serious	O
consequences	O
.	O

